Kane Biotech Inc.
KNE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 646.49% | 111.53% | 4,579.10% | 2,008.84% | 47.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 646.49% | 111.53% | 4,579.10% | 2,008.84% | 47.51% |
| Cost of Revenue | 2,830.68% | 779.77% | 20,315.38% | 4,650.00% | 66.04% |
| Gross Profit | -0.34% | -347.22% | 2,241.14% | 1,405.71% | 42.79% |
| SG&A Expenses | 12.53% | -63.70% | 35.39% | 339.52% | 30.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.21% | -30.13% | 86.58% | 504.61% | 36.39% |
| Operating Income | 8.19% | 36.67% | 38.11% | -331.48% | -35.95% |
| Income Before Tax | 23.38% | 30.87% | 46.35% | -75.08% | -34.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.38% | 114.51% | 46.35% | -75.08% | -34.53% |
| Earnings from Discontinued Operations | -- | -2,036.99% | 153.35% | 5,455.32% | 212.89% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.99% | 33.48% | 56.78% | 1,133.19% | -16.59% |
| EBIT | 8.19% | 36.67% | 38.11% | -331.48% | -35.95% |
| EBITDA | 5.24% | 38.35% | 39.04% | -438.13% | -39.39% |
| EPS Basic | 27.85% | 36.36% | 59.26% | 1,075.00% | -11.27% |
| Normalized Basic EPS | 33.96% | 47.17% | 50.00% | -68.00% | -29.27% |
| EPS Diluted | 27.85% | 36.36% | 15.85% | 585.71% | -11.27% |
| Normalized Diluted EPS | 33.96% | 47.17% | 50.00% | -59.09% | -29.27% |
| Average Basic Shares Outstanding | 13.81% | 4.34% | 5.51% | 5.94% | 5.62% |
| Average Diluted Shares Outstanding | 13.81% | 4.34% | 5.51% | 8.21% | 5.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |